Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices.
As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions.
Our platform ecosystem combines industrialized drug delivery technology with a set of built-in and optional services that support every stage of development.
We offer a wide range of injection systems, digital health solutions,
and future-focused innovations for pharma clients.
Clinic-ready devices to accelerate trial readiness and reduce study risk
No patient should see their therapy as harming the planet. Speed defines success in clinical development. Participant recruitment constraints, lengthy dose-finding protocols, and device bridging timelines create critical delays. Clear to Clinic enables the use of clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and derisk your program.
We pursue a long-term corporate strategy based on four pillars. These four pillars stand for areas of action in which we fulfill our responsibility to society as a sustainably oriented company.
We are committed to acting responsibly towards our employees, our partners and society. We are also committed to the circular economy and reducing our carbon footprint.
